UDCA plus elafibranor best for treatment-resistant PBC: Analysis
Combining ursodeoxycholic acid (UDCA) with elafibranor, an experimental oral therapy for primary biliary cholangitis (PBC), may be the best treatment combination at lessening signs…
Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts will help the World Health Organization (WHO) work toward its goal of eliminating viral hepatitis as a public health threat by 2030. The every-other-year grant program, launched in…
Read MoreCombining ursodeoxycholic acid (UDCA) with elafibranor, an experimental oral therapy for primary biliary cholangitis (PBC), may be the best treatment combination at lessening signs…
The levels of more than 250 proteins are abnormal in lab-grown liver organoids, or mini-livers, derived from a mouse model of progressive familial intrahepatic…
FXR314, an investigational oral therapy, safely and effectively reduced liver fat content in adults with a severe form of fatty liver disease called metabolic…